Uwe Christians

Comparison of the effects of cyclosporin a on the metabolism of perfused rat brain slices during normoxia and hypoxia.

Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine.

Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain microvessel endothelial cells.

Cyclosporine can increase isoflurane MAC.

Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts.

CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam.

Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia-reperfusion injury.

Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT.

Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides.

Biochemical mechanisms of cyclosporine neurotoxicity.

Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A.

Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors.

Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors.

Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates.

The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts.

Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects.

Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness.

Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure.

Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients.

Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages.

Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples.

Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood.

Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics.

Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates.

Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m).

Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing.

Impact of organ preservation using HTK for graft flush and subsequent storage in UW in rat kidney transplantation.

Functional interactions between P-glycoprotein and CYP3A in drug metabolism.

Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome.

Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction.

Cyclosporin twice or three times daily dosing in pediatric transplant patients - it is not the same!

Prolonged survival of porcine hepatocytes in cynomolgus monkeys.

HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma.

Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization-MS.

Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients.

Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus.

Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin.

Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension.

Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients.

Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus.

Pharmacokinetics of mycophenolate mofetil and sirolimus in children.

Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges.

A metabonomic and proteomic analysis of changes in IMCD3 cells chronically adapted to hypertonicity.

Characterization of sirolimus metabolites in pediatric solid organ transplant recipients.

Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101.

An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma.

Comparison of the quantification of acetaminophen in plasma, cerebrospinal fluid and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry.

The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study.

Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.

Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function.

Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation.

Enhanced leukocyte HIF-1alpha and HIF-1 DNA binding in humans after rapid ascent to 4300 m.

Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion.

Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.

Identification and characterization of a bacterial cytochrome P450 for the metabolism of diclofenac.

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.

Irradiation alters selection for oncogenic mutations in hematopoietic progenitors.

Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry.

Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study.

Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism.

Bioequivalence testing of immunosuppressants: concepts and misconceptions.

Effects of lovastatin on breast cancer cells: a proteo-metabonomic study.

Characterization of potential allergens in fenugreek (Trigonella foenum-graecum) using patient sera and MS-based proteomic analysis.

Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals.

Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model.

Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice.

Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose.

Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability.

The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study.

Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism.

Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial.

Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.

Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months.

Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions.

Quantification of 15-F2t-isoprostane in human plasma and urine: results from enzyme-linked immunoassay and liquid chromatography/tandem mass spectrometry cannot be compared.

Liquid chromatography and mass spectrometry in food allergen detection.

A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry.

How unbiased is non-targeted metabolomics and is targeted pathway screening the solution?

Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study.

Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns.

A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine.

A low blood volume LC-MS/MS assay for the quantification of fentanyl and its major metabolites norfentanyl and despropionyl fentanyl in children.

Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.

Neurobehavioural activation during peripheral immunosuppression.

Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.

MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms.

Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy.

A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.

Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism.

Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat.

Fibronectin-integrin signaling is required for L-glutamine's protection against gut injury.

Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.

Proteomics and metabolomics in renal transplantation-quo vadis?

Development and validation of an LC-MS/MS assay for the quantification of the trans-methylation pathway intermediates S-adenosylmethionine and S-adenosylhomocysteine in human plasma.

Genetic and structure-function studies of missense mutations in human endothelial lipase.

Early increase in alveolar macrophage prostaglandin 15d-PGJ2 precedes neutrophil recruitment into lungs of cytokine-insufflated rats.

Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.

Mass Spectrometry-Based Multiplexing for the Analysis of Biomarkers in Drug Development and Clinical Diagnostics- How Much is too Much?

Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter.

Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease.

Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry.

Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.

Cyclosporine induces endothelial cell release of complement-activating microparticles.

CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy.

Bioactive lipid mediators in polycystic kidney disease.

Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism.

Early effect of tidal volume on lung injury biomarkers in surgical patients with healthy lungs.

Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.

Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.

Fatty acid desaturation index in human plasma: comparison of different analytical methodologies for the evaluation of diet effects.

Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.

Endothelial dysfunction and oxidative stress in polycystic kidney disease.

Neurobehavioral consequences of small molecule-drug immunosuppression.

A high-performance liquid chromatography-tandem mass spectrometry-based targeted metabolomics kidney dysfunction marker panel in human urine.

Everolimus and sirolimus in transplantation-related but different.

Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study.

Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.

Memory-updating abrogates extinction of learned immunosuppression.

ANALYTICAL ASPECTS OF THE IMPLEMENTATION OF BIOMARKERS IN CLINICAL TRANSPLANTATION.